The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Open accessAbstract
Purpose: The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies. Patients and Methods: Previously untreated symptomatic patients with myeloma ineligible for high-dose therapy received up to nine 6-week cycles of VMP (n = 344) or MP (n = 338). Results: With a median follow-up of 36.7 months, there was a 35% reduced risk of death with VMP versus MP (hazard ratio, 0.653; P < .001); median OS was not reached with VMP versus 43 months with MP; 3-year OS rates were 68.5% versus 54.0%. Response rates to subsequent thalidomide- (41% v 53%) and lenalidomide-based therapies (59% v 52%) appeared similar after VMP or MP; response rates to subsequent bortezomib-based therapy were 47% versus 59%. Among patients treated with VMP (n = 178) and MP (n = 233), median survival from start of subsequent therapy was 30.2 and 21.9 months, respectively, and there was no difference in survival from salvage among patients who received subsequent bortezomib, thalidomide, or lenalidomide. Rates of adverse events were higher with VMP versus MP during cycles 1 to 4, but similar during cycles 5 to 9. With VMP, 79% of peripheral neuropathy events improved within a median of 1.9 months; 60% completely resolved within a median of 5.7 months. Conclusion: VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy. First-line bortezomib use does not induce more resistant relapse. VMP used upfront appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent–based treatment until relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Facon, T., Mary, J. Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 869
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053583 · Cited by 739
Recent major improvement in long-term survival of younger patients with multiple myeloma
Brenner, H., Gondos, A., & Pulte, D. (2008) · Blood · doi:10.1182/blood-2007-08-104984 · Cited by 535
Mateos, M.-V., Hernández, J.-M., Hernández, M.-T., Gutiérrez, N.-C., Palomera, L., Fuertes, M., Díaz-Mediavilla, J., Lahuerta, J.-J., de la Rubia, J., Terol, M.-J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-019778 · Cited by 389
Self-citationHulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0948 · Cited by 381
Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149427 · Cited by 358
Self-citationRichardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305
Self-citationRichardson, P. G., Xie, W., Mitsiades, C., Chanan-Khan, A. A., Lonial, S., Hassoun, H., Avigan, D. E., Oaklander, A. L., Kuter, D. J., Wen, P. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3087 · Cited by 274
Self-citationBarlogie, B., Pineda-Roman, M., van Rhee, F., Haessler, J., Anaissie, E., Hollmig, K., Alsayed, Y., Waheed, S., Petty, N., Epstein, J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-145235 · Cited by 225
Kastritis, E., Zervas, K., Symeonidis, A., Terpos, E., Delimbassi, S., Anagnostopoulos, N., Michali, E., Zomas, A., Katodritou, E., Gika, D., et al. (2009) · Leukemia · doi:10.1038/leu.2008.402 · Cited by 187
Self-citationRosiñol, L., Oriol, A., Mateos, M., Sureda, A. M., García-Sánchez, P., Gutierrez, N. C., Alegre, A. M., Lahuerta, J. J., de la Rubia, J., Herrero, C. P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3323 · Cited by 118
Self-citationTreatment of newly diagnosed myeloma
Palumbo, A., & Rajkumar, S. V. (2008) · Leukemia · doi:10.1038/leu.2008.325 · Cited by 103
Self-citationIndividualizing Treatment of Patients With Myeloma in the Era of Novel Agents
Miguel, J. F. S., Harousseau, J., Joshua, D., & Anderson, K. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2546 · Cited by 90
Mateos, M., Hernández‐Rivas, J. M., Hernández, M., Gutierrez, N. C., Palomera, L., Fuertes, M., Garcia-Sanchez, P., Lahuerta, J. J., de la Rubia, J., Terol, M. J., et al. (2008) · Haematologica · doi:10.3324/haematol.12106 · Cited by 86
Self-citationHarousseau, J., Mathiot, C., Attal, M., Marit, G., Caillot, D., Hulin, C., Facon, T. T. F., Webb, I. J., Avet‐Loiseau, H., & Moreau, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8505 · Cited by 77
Cavo, M., Tacchetti, P., Patriarca, F. F., Petrucci, M. T., Pantani, L., Ceccolini, M., Galli, M., Raimondo, F. D., Crippa, C., Zamagni, E., et al. (2008) · Blood · doi:10.1182/blood.v112.11.158.158 · Cited by 71
Self-citationRichardson, P. G. G., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D., Ghobrial, I. M., Schlossman, R. L., Mazumder, A., Munshi, N. C., et al. (2008) · Blood · doi:10.1182/blood.v112.11.92.92 · Cited by 69
Self-citationWolf, J. L., Richardson, P. G. G., Schuster, M. K., LeBlanc, A. L., Walters, I. B., & Battleman, D. S. (2008) · PubMed · Cited by 63
Self-citationAn Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple Myeloma
Conner, T., Doan, Q. D., Walters, I. B., LeBlanc, A. L., & Beveridge, R. A. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.016 · Cited by 50
Wijermans, P., Schaafsma, M. R., van Norden, Y., Ammerlaan, R., Wittebol, S. H., Sinnige, H. A. M., Zweegman, S., van Marwijk-Kooy, M., van de Griend, R. J., Lokhorst, H. M., et al. (2008) · Blood · doi:10.1182/blood.v112.11.649.649 · Cited by 50
Morgan, G. J., Jackson, G., Davies, F. E., et al. (2008) · Blood · doi:10.1182/blood.v112.11.656.656 · Cited by 50
Waage, A., Gimsing, P., Juliusson, G., Turesson, I., & Fayers, P. M. (2007) · Blood · doi:10.1182/blood.v110.11.78.78 · Cited by 47
Mateos, M., Oriol, A., Martínez‐López, J., Cibeira, M. T., de Paz, R., Terol, M. J., García‐Laraña, J., Bengoechea, E., Martínez, R., Martín, A., et al. (2008) · Blood · doi:10.1182/blood.v112.11.651.651 · Cited by 30
Self-citationPetrucci, M. T., Blau, I. W., Corradini, P., Dimopoulos, M. A., Drach, J. W., Giraldo, P., Teixeira, A., & Bladé, J. (2008) · Blood · doi:10.1182/blood.v112.11.3690.3690 · Cited by 12
Self-citation
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Self-citationBortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 741
Self-citationProteasome inhibitors in multiple myeloma: 10 years later
Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L. (2012) · Blood · doi:10.1182/blood-2012-04-403733 · Cited by 490
Self-citation
Metadata
- Authors
- Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., Dmoszynska, A., Abdulkadyrov, K. M., Schots, R., Jiang, B., Esseltine, D. L., Liu, K., Cakana, A., van de Velde, H., & San Miguel, J. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-05-01
- Volume
- 28
- Issue
- 13
- Pages
- 2259-2266
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103289287
- Cited by
- 433
- References
- 28
- FWCI
- 29.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.